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Abstract
Background: Therapeutic monoclonal anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-
4) antibodies are associated with immune-mediated enterocolitis. The aim of this study was to 
provide a detailed description of this entity.
Methods: We included patients with endoscopic signs of inflammation after anti-CTLA-4 infusions 
for cancer treatment. Other causes of enterocolitis were excluded. Clinical, biological and 
endoscopic data were recorded. A single pathologist reviewed endoscopic biopsies and colectomy 
specimens from 27 patients. Patients with and without enterocolitis after ipilimumab-treated 
melanoma were compared, to identify clinical factors associated with enterocolitis.
Results: Thirty-nine patients with anti-CTLA-4 enterocolitis were included (ipilimumab n  =  37; 
tremelimumab n = 2). The most frequent symptom was diarrhoea. Ten patients had extra-intestinal 
manifestations. Most colonoscopies showed ulcerations involving the rectum and sigmoid, 66% 
of patients had extensive colitis, 55% had patchy distribution and 20% had ileal inflammation. 
Endoscopic colonic biopsies showed acute colitis in most patients, while half of the patients had 
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13 patients (37%). Twelve patients required infliximab, of whom 10 (83%) responded. Six patients 
underwent colectomy (perforation n = 5; toxic megacolon n = 1); one of them died postoperatively. 
Four patients had a persistent enterocolitis at follow-up colonoscopy. Patients with enterocolitis 
were more frequently prescribed NSAIDs compared with patients without enterocolitis (31 vs 5%, 
p = 0.003).
Conclusions: Ipilimumab and tremelimumab may induce a severe and extensive form of 
inflammatory bowel disease. Rapid escalation to infliximab should be advocated in patients who 
do not respond to steroids. Patients treated with anti-CTLA-4 should be advised to avoid NSAIDs.
Key Words:  Anti-CTLA-4; enterocolitis; ipilimumab
1. Introduction
Anti-tumour immunotherapy has become a major therapeutic tool 
in oncology. Therapeutic monoclonal antibodies against cytotoxic 
T-lymphocyte-associated antigen 4 (CTLA-4) have been tested and 
are now routinely prescribed in cancer patients.
T-cell activation requires binding of the T-cell receptor to the 
antigen in association with MHC molecules. It also needs binding of 
CD80 and CD86 ligands on the antigen-presenting cells to the CD28 
co-stimulatory receptor on the T cells.1,2 CTLA-4 is a homologue of 
CD28 that binds CD80 and CD86 with higher affinity, and thereby 
down-regulates T-cell activation. Anti CTLA-4 monoclonal antibod-
ies block its interaction with CD80 and CD86 and favours CD28 
engagement and consequently T-cell activation and proliferation.3–5 
Anti-CTLA-4 antibodies might also induce the depletion of regula-
tory T cells (Tregs), which express CTLA-4. These cells are suscep-
tible to antibody-dependent cell-mediated cytotoxicity after binding 
of anti-CTLA-4 antibody to CD16-expressing monocytes and mac-
rophages.6–9 In summary, anti CTLA-4 monoclonal antibodies exert 
their anti-tumour effect by T-cell activation and Treg depletion.
Ipilimumab is a fully human IgG1 monoclonal antibody that 
binds to CTLA-4. Ipilimumab increases overall survival in patients 
with metastatic or advanced melanoma.10–12 It received approval in 
2011 for the treatment of metastatic melanoma from the United States 
Food and Drug Administration and the European Medicines Agency. 
Ipilimumab has also been proposed for the treatment of lung,13 ovar-
ian,14,15 renal16 and prostate carcinoma.17,18 Tremelimumab is a fully 
human IgG2 monoclonal antibody that also blocks CTLA-4. It has 
been evaluated in the treatment of melanoma,19–21 mesothelioma22 
and prostate,23 pancreatic24 and hepatocellular25 carcinomas.
Blockade of CTLA-4 activates a large repertoire of T cells, not 
only tumour-specific T cells. It is therefore not unexpected that 
patients treated with ipilimumab may have immune-related events. 
Enterocolitis is among the most frequent immune-related adverse 
events associated with ipilimumab. Approximately one-third of 
patients treated with ipilimumab have diarrhoea, while colitis is 
observed in 7–22% of patients.19,20,26–28 Ipilimumab-induced entero-
colitis has been described in case reports, small case series (including 
<10 patients) and data from clinical trials, all summarized in a recent 
systematic review.29 We are not aware of any publication reporting 
tremelimumab-induced enterocolitis.
Gastroenterologists are increasingly faced with anti-CTLA-4-
induced enterocolitis, particularly the most severe forms. There is a 
need for more information, such as inflammation site and endoscopic 
features, as well as outcomes with medical and surgical treatment. 
In this report we provide a detailed description of anti-CTLA-4-in-
duced enterocolitis in a relatively large series of patients referred to 
inflammatory bowel disease (IBD) specialists. Our findings suggest 
that anti-CTLA-4-induced enterocolitis is a particular form of IBD 
with similarities to both colonic Crohn’s disease and ulcerative 
colitis.
2. Methods
We recorded anti-CTLA-4 enterocolitis cases observed between 
October 2010 and September 2014 following a call to the Groupe 
d’Etudes Thérapeutiques dans les Affections Inflammatoires 
Digestives (GETAID), a French-speaking group of gastroenterolo-
gists that performs clinical studies in IBD in France and Belgium. 
A  majority of patients were recruited from Gustave Roussy and 
referred to the Gastroenterology Department of Bicêtre University 
Hospital. Patients were eligible for inclusion if they had endoscopic 
signs of inflammation after having received anti-CTLA-4 infusion. 
Other causes of enterocolitis, such as ischaemia and infection (stool 
test for bacterial pathogens and Clostridium difficile toxin), were 
excluded.
Ipilimumab was administered by intravenous infusion every 3 
weeks during an induction phase, at a dose of 3 or 10 mg/kg of body 
weight. Patients could continue ipilimumab infusions with a mainte-
nance treatment every 12 weeks in case of tumour response or stable 
disease. Tremelimumab was administered by intravenous infusion 
every 4 weeks, at a dose of 3 or 10 mg/kg of body weight. Socio-
demographic, clinical, biological and endoscopic data were recorded 
using pre-specified forms. Gastric, duodenal and colonic endoscopic 
biopsies and colectomy specimens of patients referred from Gustave 
Roussy to Bicêtre Hospital were reviewed by a single pathologist (C. 
Mussini).
We classified anti-CTLA-4 enterocolitis into 3 groups based on 
clinical management of the enterocolitis: (1) those who had a sponta-
neous favourable outcome; (2) those who required steroids; and (3) 
those who required immediate colectomy. For each of these groups, 
we noted the short- and long-term outcomes of the enterocolitis. We 
also recorded the effects of anti-CTLA-4 re-infusions.
Finally, the association between clinical factors and occurrence of 
enterocolitis was studied. For this purpose, patients with melanoma 
treated by ipilimumab who had enterocolitis were compared with a 
control group of patients with melanoma treated with ipilimumab 
at Gustave Roussy and who did not have enterocolitis. We also 
performed a sensitivity analysis restricted to the patients treated at 
Gustave Roussy. For this purpose, we compared patients with mela-
noma and enterocolitis treated with ipilimumab at Gustave Roussy 
with a control group of patients with melanoma and no enterocol-
itis, treated with ipilimumab at Gustave Roussy.
Quantitative data are described with the median (range) and qual-













data were compared using Student's test and qualitative data using 
the χ2 test.
The study was submitted to the ethics committee of Paris-Ile de 
France VII. This committee stated that there was no ethical issue 
related to this study.
3. Results
Seven centres participated in this study. Thirty-nine patients with anti-
CTLA-4 enterocolitis were reported. The baseline characteristics of these 
patients are summarized in Table 1. Most patients received ipilimumab 
for melanoma; none of them received any concomitant chemotherapy 
or immunosuppressive treatment. Two patients (5%) received tremeli-
mumab and gefitinib for non-small-cell lung carcinoma. Eighteen patients 
received anti-CTLA-4 at a dose of 3 mg/kg, five received a dose of 10 mg/
kg and 16 received either 3 or 10 mg/kg in blinded trials (GEFTREM trial 
NCT02040064; BMS CA184-169 trial NCT01515189; Ipilimumab + 
Stereotactic Radiotherapy EUDRACT 2012-000852-32; MelIpiRx trial 
EUDRACT 2010-020317-93; EORTC 18071 trial EUDRACT 2007-
001974-10). The median number of anti-CTLA-4 infusions was 2 (1–8). 
Eight patients (20.5%) had a personal history of autoimmune or inflam-
matory disorders prior to anti-CTLA-4 infusion. One patient (2.5%) 
had a family history of Crohn’s disease.
3.1. Clinical characteristics of anti-CTLA4 
enterocolitis
The clinical characteristics of patients with anti-CTLA-4 enterocolitis 
are described in Table 1. The most frequent symptoms were diarrhoea 
(92%), abdominal pain (82%), haematochezia (64%), fever (46%) 
and vomiting (36%). Median body weight loss was 8% (0–27). In 
the 36 patients who received anti-CTLA-4 without interruption, the 
median time between the first infusion of anti-CTLA-4 and symp-
toms was 34 days (3–91). Three patients discontinued ipilimumab 
for several months, and after re-introduction of treatment developed 
enterocolitis after 1, 4 and 4 infusions respectively. The median time 
between first symptoms and diagnosis of enterocolitis was 14 days 
(1–77). One patient had aphthous mouth ulcers and 3 patients had 
anal lesions (2 fistulas with abscesses, 2 fissures). Ten patients had one 
or more extra-intestinal manifestations associated with anti-CTLA-4 
enterocolitis, namely arthralgia (n = 5), hypophysitis (n = 2), hepatitis 
(n = 1), nephritis (n = 1), pericarditis (n = 1), pancreatitis (n = 1), thy-
roiditis (n = 1) and pyoderma gangrenosum (n = 1). Five patients had 
a colon perforation, of whom 1 had a colonic obstruction and 4 had 
intra-abdominal abscesses. One of these patients died.
3.2. Laboratory analyses
The main biological abnormalities were anaemia (median haemo-
globin level 11.6 g/dL [7–15]), increased serum C-reactive protein 
(CRP) (111 mg/L [5–622]) and low serum albumin levels (27 g/L 
[14–39]). Faecal calprotectin, measured in 8 patients at the time 
of enterocolitis, was markedly increased (1755 µg/g [299–12 900]). 
Anti-Saccharomyces cerevisiae antibodies [ASCA] and perinuclear 
antineutrophilic cytoplasmic antibodies [pANCA] were positive in 1 
out of 4 and 1 out of 18 patients respectively.
3.3. Endoscopic findings in anti-CTLA-4 
enterocolitis (Figure 1)
All 39 patients had endoscopic inflammation of the colon. All under-
went at least sigmoidoscopy, 33 had total colonoscopy and 25 also 
underwent ileocolonoscopy. The most severe endoscopic lesions were 
erythema in 3 patients (8%), erosion in 5 (13%) and ulceration in 31 
(79%). Ulcerations were observed in 17/18 patients (94%) treated 
with 3 mg/kg anti-CTLA-4 infusions and in 3/5 patients (60%) 
treated with 10 mg/kg. In 38/39 patients (97%) there was involve-
ment of the rectum and/or sigmoid. Extensive colitis was observed 
in 23/35 patients (66%) and a patchy distribution in 18/33 patients 
(55%). Five patients had ileitis, of whom 3 had ileal ulcerations and 
2 had ileal erythema. The site of ileal and colonic inflammation is 
shown in Table 2.
Among the 22 patients who underwent upper gastrointestinal 
endoscopy, one had a 2-cm ulceration of the mid-oesophagus, 9 had 
gastritis and 2 had erosive duodenitis.
3.4. Histological findings in anti-CTLA-4 
enterocolitis (Figure 2)
The colonic biopsies of the 27 patients referred from Gustave 
Roussy to Bicêtre Hospital were reviewed by a single pathologist (C. 
Mussini). Among these, 26 had histological features of acute colitis, 
including either focal active colitis with patchy crypt abscesses or 
diffuse mucosal acute inflammation. There was no basal plasmacy-
tosis, no atrophy, no distortion, and no branching or budding of 
crypts. Mild eosinophilic infiltrates and mild apoptosis were found 
in 19/27 and 11/27 patients respectively. Only one patient had mild 
chronic colitis, characterized by focal crypt distortion and branch-
ing. Two patients had superficial granulomas. There were no CMV 
inclusions in colonic biopsies.
The four colectomy specimens analysed showed extensive acute 
severe colitis with abrupt transition between ulcerations and normal 
Table  1. Characteristics of patients with anti-CTLA-4-induced 
enterocolitis (N = 39).
Characteristic 
Median age, years (range) 63 23–85
Male sex 20 51%
Personal history of immune disorder
 Arthritis 3 8%
 Dermatitis 5 13%
 Thyroid dysfunction 2 5%
 Total number of patients 8 21%
Anti-CTLA-4 indication
 Melanoma 35 90%
 Prostate carcinoma 2 5%
 Lung carcinoma 2 5%
Tachycardia (>100 beats/min) 22 56%
Fever 18 46%
Median body weight loss, %, (range) 8% 0–27%
Nausea–vomiting 14 36%
Diarrhoea 36 92%
 Median number of stools/24h (range) 10 1–20
Haematochezia 25 64%
Abdominal pain 32 82%
 Mild 4 13%
 Moderate 18 56%
 Severe 10 31%
Oral aphthoid ulcers 1 3%
Anal fissuration 2 5%
Anal fistula with abscess 2 5%
Intra abdominal abscess  4 10%
Colonic obstruction 1 3%
Colonic perforation 5 13%
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mucosae. Only one patient had an association of extensive acute coli-
tis with focal chronic colitis. None of the patients had granuloma.
Duodenal biopsies were available for review in 18 patients. The 
duodenal mucosa was normal in 8 patients. Ten patients had chronic 
duodenitis (crypt distortion, focal and heterogeneous villus shorten-
ing, increased eosinophils and mononuclear inflammatory cells in the 
lamina propria, and hyperplasia of Brunner’s glands), often with a 
patchy distribution and mild activity. Granulomatous duodenitis was 
found in 2 patients. Gastric biopsies were available in 13 patients. 
Gastric mucosa was normal in 2 patients. Seven patients had chronic 
gastritis without Helicobacter pylori, often with scanty inflamma-
tory cells and mildly active or inactive lesions, and 1 had focal active 
gastritis without H. pylori. Two patients had chronic gastritis with 
H. pylori infestation. One patient had granulomatous gastritis.
3.5. Outcomes (Figure 3)
Three patients had a spontaneous favourable evolution. One patient 
underwent emergency partial colectomy 7  days after diagnosis of 
anti-CTLA-4 enterocolitis, without having received any medical treat-
ment. The other 35 patients received steroids (median dose 60 mg of 
prednisolone per day [40–120]). Overall, 13 patients out of 35 (37%) 
reached complete clinical remission with steroids only, including 2 
patients who relapsed and subsequently responded to a new course 
of steroids. Twelve patients required infliximab, including one patient 
who received it postoperatively; 6 of them were treated with a dose 
of 3 mg/kg of anti-CTLA-4 and 6 with a blinded dose. All responded 
except for 2 patients who required emergency colectomy because of 
severe relapse. Six patients (15%) underwent colectomy, because of 
perforation (n = 5) or toxic megacolon (n = 1). Three patients had a 
subtotal colectomy (total colectomy with ileostomy and sigmoidos-
tomy for 2 patients and rectal stump for 1 patient). Three patients 
had partial colectomy. Among them, 2 patients had a left colectomy 
(1 had a transverse colostomy and a sigmoidostomy and 1 had a 
transverse colostomy and a rectal stump), and one patient had a right 
colectomy with ileostomy and transverse colostomy. Patients with 
partial colectomy had severe inflammation of the remaining colon. 
Among patients with partial colectomy, 1 had a subsequent subto-
tal colectomy; another had postoperative infliximab infusion, and 
the third patient had percutaneous drainage of an intra-abdominal 
abscess, postoperatively. The postoperative course was complicated 
A
B
Figure 1. Endoscopic findings in patients with anti CTLA-4 enterocolitis. (A) 
erythematous colitis; (B) ulcerated colitis.
Table  2. Site of inflammation on colonoscopies of patients with 
anti-CTLA-4 enterocolitis. Variation in the denominator is due to 
incomplete colonoscopy.
Site of inflammation (n/N, %)
Ileum 5/25 20
Ascending colon 27/33 82
Transverse 28/35 80
Descending colon 35/38 92
Sigmoid colon 36/38 95
Rectum 32/39 82
Extensive colitis 23/35 66
Patchy distribution 18/33 55
A
B
Figure  2. Histological findings of anti-CTLA-4 enterocolitis and duodenitis. 
(A) Acute colitis. Numerous neutrophils are present in the lamina propria 
with cryptic abscesses (haematoxylin–eosin–saffron [HES] ×200). (B) 
Chronic duodenitis. Shortened villi and increased amount of mononuclear 













in these 6 patients, including 1 postoperative death. This patient was 
an 83-year-old man with metastatic melanoma. He had received 
high-dose intravenous steroids for 8  days for ipilimumab-induced 
enterocolitis, and improved clinically. Subsequently, his clinical status 
deteriorated. Spontaneous colonic perforation and an abscess were 
found. The patient underwent subtotal colectomy with Hartmann’s 
procedure, but died postoperatively. The other 5 patients had postop-
erative intra-abdominal abscesses, fistulae, evisceration, sepsis, pneu-
monia, anasarca, pulmonary embolism, cerebral thrombophlebitis 
and atrial fibrillation. One patient, who had undergone a subtotal 
colectomy, had an ileorectal anastomosis after sigmoidoscopy and 
had shown mucosal healing. In the days following restoration of con-
tinuity, he had severe diarrhoea and deep and extensive ulcerations 
of the rectum with diffuse acute colitis on biopsies. Treatment with 
adalimumab induced and maintained remission.
Nine patients in the cohort underwent follow-up colonoscopy 
at a median time of 4 months (2–7) after onset of symptoms. Five 
patients had normal follow-up colonoscopy; biopsies were taken 
in 4 of them and showed acute colitis (n  =  1), chronic colitis 
(n  =  1), lymphocytic colitis (n  =  1) and normal mucosa (n  =  1). 
Four patients had active endoscopic colitis; 2 were observed in 
patients in clinical remission, while 2 patients had persistent clini-
cal and endoscopic activity 3.5 and 6 months after onset of symp-
toms, without having received another course of anti CTLA-4 or 
any other cancer treatment. Colonic biopsies of these four patients 
with active endoscopic colitis showed either acute colitis (n = 2) or 
chronic colitis (n = 2).
Finally, six patients of the cohort had an additional infusion of 
ipilimumab after going into enterocolitis remission. Four relapsed. 
One had a spontaneous favourable evolution and achieved remis-
sion 1 month after ipilimumab withdrawal. Three patients required 
a new steroid course, 2 of them achieved complete remission and 1 
patient responded within 24 hours, but had a severe steroid-refrac-
tory relapse requiring infliximab infusion.
3.6. Clinical factors associated with ipilimumab-
induced enterocolitis
Thirty-five patients with melanoma had an ipilimumab-induced 
enterocolitis. They were compared with 38 patients with melanoma 
who were treated with ipilimumab at Gustave Roussy and who had 
no enterocolitis (Table 3). The use of NSAIDs was more frequent 
among patients who had enterocolitis (31 vs 5%, p = 0.003). This 
result was confirmed by a sensitivity analysis restricted to the 24 
patients with enterocolitis, who were followed at Gustave Roussy 
(29 vs 5%, p = 0.009).
4. Discussion
This study confirms that both ipilimumab and tremelimumab are 
associated with a risk of severe enterocolitis and highlights the 
similarities between anti-CTLA-4-induced enterocolitis and IBD. 
It shares some features with Crohn’s disease. Approximately half 
of the patients have patchy endoscopic inflammation of the colon. 
Chronic inflammation of the duodenum is frequently observed, 
while some patients have ileitis and perianal involvement, suggest-
ing that anti-CTLA-4 antibodies provoke diffuse inflammation of 
the gastrointestinal tract, predominantly in the colon. Some patients 
have granulomas on duodenal and colonic biopsies. Noticeably, one 
patient had a severe relapse of colitis of the rectal remnant after res-
toration of continuity and subtotal colectomy. This is similar to the 
role of the faecal stream in the recurrence of Crohn’s disease after 
surgical resection.30 Although unique, this observation suggests that 
altered crosstalk between the gut immune system and faecal micro-
biota has a role in anti-CTLA-4-induced enterocolitis. However, 
anti-CTLA-4-induced enterocolitis is also similar to ulcerative coli-
tis. It may be associated with a diffuse and continuous inflamma-
tion of the colon without small intestinal involvement. Yet, in this 
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showed acute and not chronic inflammation, as would be expected 
in both ulcerative colitis and Crohn’s disease. These findings suggest 
that ipilimumab-induced enterocolitis is a peculiar entity that shares 
features with both Crohn’s disease and ulcerative colitis. This is sup-
ported by a longitudinal study by Berman et al.,31 which has shown 
that ipilimumab induces antibodies to enteric flora, such as pANCA 
and anti OmpC. These antibodies are markers of a dysregulated 
mucosal immune environment in IBD and are not found in diverticu-
litis and infection. However, in this longitudinal study the pattern of 
ipilimumab-induced antibodies to microbial flora was distinct from 
that in classical IBD. Taken together, these findings support the con-
cept that ipilimumab-induced enterocolitis is a peculiar form of IBD. 
Patients with anti-CTLA-4-induced enterocolitis may respond to 
steroids and infliximab therapy. Considering the short delay between 
anti-CTLA-4 infusion and onset of enterocolitis (34 days), as well 
as the high rate of colonic ulcerations, extensive colitis, steroid fail-
ure, complications and colectomy, anti-CTLA4-induced enterocolitis 
appears to be an accelerated and severe form of IBD.
This study provides new information about the clinical manage-
ment of anti CTLA-4-induced enterocolitis. Firstly, most patients had 
endoscopic inflammation accessible to flexible sigmoidoscopy and 
could therefore avoid complete colonoscopy for diagnostic purposes. 
Secondly, 37% of patients were successfully treated with steroids. By 
comparison, 10 out of 12 patients (83%) responded to infliximab 
after they had failed to improve with steroids. Therefore, due to its 
severe course, patients with anti-CTLA-4-induced enterocolitis should 
be carefully monitored and a rapid escalation to infliximab should be 
advocated in patients who do not respond to steroids. Thirdly, when 
required, colectomy should be subtotal and not segmental since, in 
most cases, anti CTLA-4-induced enterocolitis involves the whole 
colon. Fourthly, patients with anti CTLA-4-induced enterocolitis are 
likely to relapse when they receive another course of the same drug. 
Whether steroid or infliximab maintenance treatment may prevent 
relapse of colitis in this setting remains unknown. Fifthly, endo-
scopic ulcerations and infliximab requirement were no more frequent 
among patients receiving a high dose of anti-CTLA-4, suggesting 
that the severity of anti-CTLA-4 enterocolitis is not dose-dependent. 
Sixthly, patients with ipilimumab-induced enterocolitis were more 
frequently prescribed NSAIDs compared with those without entero-
colitis. This is in line with the predisposing role of NSAIDs in IBD.32 
Patients treated with anti-CTLA4 should be advised to avoid these 
drugs. Lastly, and importantly, some patients had endoscopic inflam-
mation, with or without symptoms, several months after the onset of 
enterocolitis, suggesting that, in some patients, anti-CTLA-4-induced 
enterocolitis may progress to chronic IBD.
Anti-CTLA-4 enterocolitis represents a model of T-cell-induced 
colitis in humans. Recently, germline heterozygous mutations of 
CTLA-4 have been reported in humans.33,34 These patients had 
early-onset Crohn’s disease and systemic autoimmunity (lung infil-
trates, cytopenia). Dysregulation of FoxP3+ Tregs, hyperactivation 
of effector T cells, increased circulating memory T cells and lym-
phocytic infiltration of target organs were observed. Enterocolitis is 
almost constant in patients with CTLA-4 haplo-insufficiency and is 
one of the most frequent immune disorders associated with anti-
CTLA-4 treatment of cancer. This might be due to the crucial role 
played by CTLA-4 in gut-residing Tregs. Indeed, induction and dif-
ferentiation of peripheral Tregs in the intestine requires CTLA-4/
CD86 and to a lesser extent CTLA-4/CD80 interactions.35 Thus, 
anti-CTLA-4 enterocolitis could be due to a decrease in differentia-
tion of peripheral Tregs in the intestine. Further studies are needed to 
elucidate the precise mechanisms of anti-CTLA-4-induced enterocol-
itis. Due to the similarities between IBD and CTLA-4-induced enter-
ocolitis, these studies could shed some light on IBD mechanisms.
This study has strengths. All patients had lower gastrointestinal 
endoscopy, and most of them had colonoscopy. Most pathological 
specimens of gastrointestinal tissue were reviewed by a single pathol-
ogist. In addition, the patients included were managed by physicians 
specializing in IBD care. However, this strength is also a limitation. 
The patients described in this study were referred to IBD specialists 
and were therefore probably selected for their severity. Therefore, 
this study probably overestimates the severity of ipilimumab-
induced enterocolitis.
In summary, this study describes the enterocolitis occurring as 
a complication of treatment with ipilimumab and tremelimumab 
for cancer. Anti-CTLA-4-induced enterocolitis represents a unique 
model of T-cell-induced colitis in humans and shares several fea-
tures with IBD. These colitis forms may be severe and may pro-
gress to chronic IBD. Early recognition of the disease, and close 
collaboration between prescribers of anti-CTLA-4, gastroenter-
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Table 3. Clinical factors associated with ipilimumab-induced entrocolitis in patients with melanoma.
Factor Control group (N = 38) Enterocolitis group (N = 35) p value*
Median age, years (range) 64 (36–80) 64 (23–85) 0.940
Male sex 21 (55%) 18 (51%) 0.743
Personal history of immune disorder 4 (11%) 8 (23%) 0.155
NSAIDs prior to ipilimumab 2 (5%) 11 (31%) 0.003
Antibiotics prior to ipilimumab 7 (18%) 7 (20%) 0.864
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